431 related articles for article (PubMed ID: 17944704)
21. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Fothergill A; Ghannoum M; Manavathu E; Ostrosky-Zeichner L; Pfaller M; Rinaldi M; Schell W; Walsh T
J Clin Microbiol; 2005 Oct; 43(10):5243-6. PubMed ID: 16207990
[TBL] [Abstract][Full Text] [Related]
22. In vitro testing of Aspergillus fumigatus clinical isolates for susceptibility to voriconazole, amphotericin B and itraconazole: comparison of sensititre versus NCCLS M38-A using two different inocula.
Drago M; Scaltrito MM; Cariani L; Morace G
J Chemother; 2004 Oct; 16(5):474-8. PubMed ID: 15565915
[TBL] [Abstract][Full Text] [Related]
23. Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining.
Lass-Flörl C; Nagl M; Speth C; Ulmer H; Dierich MP; Würzner R
Antimicrob Agents Chemother; 2001 Jan; 45(1):124-8. PubMed ID: 11120954
[TBL] [Abstract][Full Text] [Related]
24. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.
Oakley KL; Moore CB; Denning DW
J Antimicrob Chemother; 1998 Jul; 42(1):91-4. PubMed ID: 9700534
[TBL] [Abstract][Full Text] [Related]
25. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
Philip A; Odabasi Z; Rodriguez J; Paetznick VL; Chen E; Rex JH; Ostrosky-Zeichner L
Antimicrob Agents Chemother; 2005 Aug; 49(8):3572-4. PubMed ID: 16048988
[TBL] [Abstract][Full Text] [Related]
26. Use of spectrophotometric reading for in vitro antifungal susceptibility testing of Aspergillus spp.
Dannaoui E; Persat F; Monier MF; Borel E; Piens MA; Picot S
Can J Microbiol; 1999 Oct; 45(10):871-4. PubMed ID: 10907424
[TBL] [Abstract][Full Text] [Related]
27. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
Verweij PE; Mensink M; Rijs AJ; Donnelly JP; Meis JF; Denning DW
J Antimicrob Chemother; 1998 Sep; 42(3):389-92. PubMed ID: 9786480
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
[TBL] [Abstract][Full Text] [Related]
29. Serotonin (5-HT) enhances the activity of amphotericin B against Aspergillus fumigatus in vitro.
Heller I; Leitner S; Dierich MP; Lass-Flörl C
Int J Antimicrob Agents; 2004 Oct; 24(4):401-4. PubMed ID: 15380269
[TBL] [Abstract][Full Text] [Related]
30. Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999.
Chandrasekar PH; Cutright JL; Manavathu EK
Diagn Microbiol Infect Dis; 2001 Dec; 41(4):211-4. PubMed ID: 11777662
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.
Pfaller MA; Duncanson F; Messer SA; Moet GJ; Jones RN; Castanheira M
Antimicrob Agents Chemother; 2011 Nov; 55(11):5155-8. PubMed ID: 21844312
[TBL] [Abstract][Full Text] [Related]
32. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Gomez-Lopez A; Garcia-Effron G; Alcazar-Fuoli L; Mellado E; Buitrago MJ; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937
[TBL] [Abstract][Full Text] [Related]
33. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus.
Manavathu EK; Abraham OC; Chandrasekar PH
Clin Microbiol Infect; 2001 Mar; 7(3):130-7. PubMed ID: 11318811
[TBL] [Abstract][Full Text] [Related]
34. In vitro susceptibility of Aspergillus spp. clinical isolates to albendazole.
Berthet N; Faure O; Bakri A; Ambroise-Thomas P; Grillot R; Brugère JF
J Antimicrob Chemother; 2003 Jun; 51(6):1419-22. PubMed ID: 12716778
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
Serrano Mdel C; Valverde-Conde A; Chávez M M; Bernal S; Claro RM; Pemán J; Ramirez M; Martín-Mazuelos E
Diagn Microbiol Infect Dis; 2003 Feb; 45(2):131-5. PubMed ID: 12614985
[TBL] [Abstract][Full Text] [Related]
36. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Swinne D; Watelle M; Van der Flaes M; Nolard N
Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
[TBL] [Abstract][Full Text] [Related]
37. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method.
Espinel-Ingroff A; Rezusta A
J Clin Microbiol; 2002 Jun; 40(6):2101-7. PubMed ID: 12037072
[TBL] [Abstract][Full Text] [Related]
38. In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs.
Pfaller JB; Messer SA; Hollis RJ; Diekema DJ; Pfaller MA
J Clin Microbiol; 2003 Mar; 41(3):1126-9. PubMed ID: 12624040
[TBL] [Abstract][Full Text] [Related]
39. In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole.
Dannaoui E; Persat F; Monier MF; Borel E; Piens MA; Picot S
J Antimicrob Chemother; 1999 Oct; 44(4):553-5. PubMed ID: 10588320
[TBL] [Abstract][Full Text] [Related]
40. [Activity of itraconazole against clinical isolates of Aspergillus spp. and Fusarium spp. determined by the M38-P NCCLS method].
Carrillo-Muñoz AJ; Quindós G; Ruesga M; Brió S; del Valle O; Rodríguez V; Hernández-Molina JM; Cantón E; Pemán J; Santos P
Rev Esp Quimioter; 2001 Sep; 14(3):281-5. PubMed ID: 11753450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
